Results 211 to 220 of about 63,889 (276)

Identification of antibiotic allergies in children using prescribing patterns in the electronic medical record

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3161-3168, September 2026.
Background By age three, 5%–75% of children have a documented antibiotic allergy (AL). Despite this prevalence, recognition remains low because of limited clinician knowledge and time. Our study evaluates a novel approach to identifying AL using electronic medical record (EMR) prescription patterns.
Georgia Koutsaplis, Kailey Tang, Renee Dimond, Alice Lei, Amanda Wilkins, Amanda Gwee   +5 more
wiley   +1 more source

Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease.

JAMA Netw Open
Lyu N, Tracy M, Schneeweiss S, Savage TJ.   +3 more
europepmc   +1 more source

TNF-α-responsive YAP1 promotes CCL20 expression in colorectal inflammation and cancer. [PDF]

Sci Rep
Chen L, Ai F, Yu W, Xiang B, Shen S, Ma J, Li X.   +6 more
europepmc   +1 more source

Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Reports of immune checkpoint inhibitor (ICI) therapy‐associated immune‐related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real‐world observational studies. Methods We conducted a systematic review of real‐world observational studies (case reports and series ...
Shea‐Lee Godin, Tyler Kingma, Ashwin Pillai, Obada Kholoki, Agnes S. Kim   +4 more
wiley   +1 more source

Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease. [PDF]

Drug Des Devel Ther
Guo YQ, Wang YT, Gao M, Liu T, Huang LH, Deng S, Li XY, Xu MD.   +7 more
europepmc   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 684-691, September 2026.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Safety evaluation of subcutaneous and intravenous administration of infliximab: a real-world study based on the FAERS database. [PDF]

Front Med (Lausanne)
Zheng X, Xie M, Luo H, Cai J, Xu R, Ling T.   +5 more
europepmc   +1 more source

Biological Activities, Medicinal Uses, and Nutritional Effects of Terminalia arjuna (Roxb. ex DC.) Wight & Arn.: Phytochemical Insights and Therapeutic Benefits in Ulcerative Colitis Management—A Detailed Review

Food Science &Nutrition, Volume 14, Issue 9, September 2026.
This graphical abstract highlights the versatile therapeutic potential and food applications of Terminalia arjuna, centering on its broad health‐promoting bioactivities. Key mechanisms described include adaptogenic, cardioprotective, gastroprotective, wound‐healing, and anti‐inflammatory effects mediated through Nrf2 and NF‐κB signaling pathways ...
Rameen Naeem, Muhammad Tauseef Sultan, Muhammad Usman Khalid, Muhammad Maaz, Ayman Furqan, Laiba Tanvir, Fabiano Travaglia, Matteo Bordiga, Mutjardah Zarrish   +8 more
wiley   +1 more source

Sweet's syndrome during anti-TNF therapy with successful rescue using a JAK inhibitor in refractory ulcerative colitis: a case report and literature review. [PDF]

Front Immunol
Shi Y, Ding J, Cheng W, He J, Da Y, Liang J.   +5 more
europepmc   +1 more source

Lonicerae Japonicae Flos as a Dietary Natural Product: Bioactive Constituents, Gut Health Modulation, and Therapeutic Potential in Ulcerative Colitis and Colorectal Cancer

Food Science &Nutrition, Volume 14, Issue 9, September 2026.
Bioactive constituents, mechanisms of action, and potential applications of Lonicerae Japonicae Flos as a dietary natural product for promoting gut health and managing ulcerative colitis and colorectal cancer. ABSTRACT Lonicerae Japonicae Flos (LJF), a traditional Chinese herb with applications in both medicine and nutrition, has emerged as a promising
Xiaoyu Huang, Letian Zhang, Zenghui Shi, Ni Zhu, Yifei Liu, Yanhong Zhou   +5 more
wiley   +1 more source